Axsome Therapeutics Inc (NASDAQ:AXSM) does about 703.71K shares in volume on a normal day but saw 732848 shares change hands in the recent trading day. The company now has a market cap of 4.06B USD. Its current market price is $85.52, marking an increase of 2.78% compared to the previous close of $83.21. The 52 week high reached by this stock is $98.40 whilst the lowest price level in 52 weeks is $55.02. The script in recent trading has seen the stock touch a high of $180 and a low of $80.
Axsome Therapeutics Inc (AXSM) has a 20-day trading average at $84.67 and the current price is -13.09% off the 52-week high compared with 55.43% distance from its 52-week low. The 50-day simple moving average of the closing price is $79.69 and its 200-day simple moving average is $76.52. If we look at the stock’s price movements over the week, volatility stands at 6.37%, which decreases to 4.00% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 55.93 to suggest the stock is neutral.
The consensus objective for the share price is $124.35, suggesting that the stock has a potential upside of 31.23% over the period. The median price target is 21.54% away from the current levels at $109.
13 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 06, 2024 when BofA Securities upgraded the stock to “Buy” and issued a price target of between $95 and $106. Morgan Stanley upgraded its price target at $90-$115.
Axsome Therapeutics Inc (AXSM) stock is up 0.61% over the week and 2.27% over the past month. Its price is 7.45% year-to-date and 16.10% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -1.27 and -5.31 for whole year. Expected sales for next quarter are $116.39M, which analysts say will come at $379.23M for the current fiscal year and next year at $647.84M. In addition, estimates put the company’s current quarterly revenue at an average of $100.38M.
Its 12-month price target is $109. To reach the target analysts have set, the stock logically needs to grow 31.23 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $80, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $180.
Outstanding shares total 47.35M with insiders holding 17.04% of the shares and institutional holders owning 82.30% of the company’s common stock. The company has a return on investment of -105.66% and return on equity of -161.69%. The beta has a value of 1.26. Price to book ratio is 39.75 and price to sales ratio is 13.94.
